India, April 8 -- BioXcel Therapeutics, Inc. (BTAI) has enrolled the first patients in a U.S. Department of War-funded phase 2a study evaluating BXCL501, its sublingual dexmedtomidine film, for the treatment of acute stress reactions.
Acute stress reactions can occur in the days and weeks following traumatic events such as motor vehicle collisions, combat exposure, shootings, or natural disasters. Symptoms may include anxiety, sleep problems, difficulty concentrating, pain, dizziness, and other physical or emotional responses. If untreated, ASR can progress into long-term post-traumatic symptoms, including PTSD and depression.
The double-blind, placebo-controlled Phase 2a trial, led by the University of North Carolina's Institute of Traum...